CombiMatrix Introduces Design-on-Demand Arrays Offering the World's Largest and Most Comprehensive Array Catalog.

NEWPORT BEACH, Calif. -- 1,423 Microbial, Eukaryotic, and Viral Genomes Made Available for Design-on-Demand(TM), Providing a Quick, Inexpensive, Flexible Solution for Whole-Genome Expression Studies

Acacia Research Corporation (Nasdaq:CBMX) (Nasdaq:ACTG) announced today that its CombiMatrix group has launched Design-on-Demand(TM) Arrays, providing researchers with the world's largest and most comprehensive catalog of microarray expression products for microbial, eukaryotic, and viral genomes. These arrays offer scientists an affordable and flexible tool to conduct whole-genome expression studies on a wide range of organisms, including Influenza, HIV, Anthrax, and SARS coronavirus. There are no minimum order requirements, no set-up fees, and no design fees.

"I recently used CombiMatrix's Design-on-Demand oligonucleotide microarrays for an organism that is not available from competing commercial sources," said Dr. Anita Sil, Assistant Professor at University of California, San Francisco. "The Design-on-Demand Arrays were designed, manufactured, and delivered within a few days, meeting my specific needs expeditiously. CombiMatrix people are easy to work with, professional, and very efficient at designing and manufacturing high-quality arrays."

"We are pleased to introduce Design-on-Demand Arrays, which offer researchers a totally flexible and personalized solution to designing arrays. We make the design process easy by leveraging our maskless CustomArray(TM) platform and bioinformatic expertise," said Michael Tognotti, Director of Sales and Marketing at CombiMatrix. "We encourage researchers to go to our CombiMatrix website at www.combimatrix.com to see the list of organisms. If your organism is not on our list, please contact our customer service department."

Some key organisms of the 1,423 include:

-  Anthrax        -  Influenza A (Bird/Human Flu)   -  Chicken
-  E. Coli O157   -  Herpes Simplex Virus           -  Papillomavirus
-  Tuberculosis   -  HIV-1                          -  SARS
-  Pneumonia      -  West Nile                      -  Plague
-  Cholera        -  Arabidopsis                    -  Reston Ebola

Design-on-Demand users benefit from many features including:

--No Design Fee, No Set-up Fee, No Minimum Order Requirement

--VRD Technology (Virtual Re-Design) at no cost

--Most up to date genomic information

--Use with standard reagents and most commercially available scanners

--Total customization and flexibility -- study any genome, any gene, or any sequence

--Rapid turnaround time

--Personalized and interactive ordering

--CombiMatrix's CustomArrays are next generation DNA microarrays that allow researchers the flexibility to select the content for their arrays with the freedom of no design fees, no set-up fees, and no minimum order requirements. CustomArrays are semiconductor-based arrays (approx. 1 cm2) integrated onto a standard 1" x 3" slide format. CombiMatrix synthesizes oligonucleotides in situ to build CustomArrays. Sensitivity and performance metrics are available at www.combimatrix.com.

ABOUT ACACIA RESEARCH CORPORATION

Acacia Research Corporation comprises two operating groups: Acacia Technologies Group and CombiMatrix Group.

The CombiMatrix group is developing a platform technology to rapidly produce customizable active biochips, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. CombiMatrix's technology has a wide range of applications including DNA synthesis/diagnostics, siRNA synthesis, drug discovery, and immunochemical detection. CombiMatrix provides DNA arrays to researchers under the CustomArray(TM) brand. CombiMatrix's Express Track(sm) drug discovery program is a systems biology approach, using its technology, to target common viral diseases with siRNA compounds.

The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia's DMT(R) technology, which is supported by 5 U.S. and 31 foreign patents, relates to audio and audio/video transmission and receiving systems commonly known as audio-on-demand, video-on-demand, and audio/video streaming, and is used for distributing digital content via several means including Internet, cable, satellite and wireless systems. Acacia's Internet Access Redirection ("IAR") technology covers redirected Internet registrations commonly used at wireless hotspots and hotels.

Acacia Research-Acacia Technologies (Nasdaq:ACTG) and Acacia Research-CombiMatrix (Nasdaq:CBMX) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.

Information about the Acacia Technologies Group and the CombiMatrix Group is available at www.acaciaresearch.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.